# Kelonia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kelonia-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.keloniatx.com
- Total disclosed funding: $50M
- Latest round: Series A (Apr 14, 2022)
- Investors on record: 3

## About

Based in Massachusetts, US, and co-founded in 2017 by Kevin Friedman, Kelonia Therapeutics, Inc., aka Kelonia, is a biotech firm offering therapeutic platform that offers clinical solutions to patients dealing with diseases such as malignants and others. In April 2026, Eli Lilly and Company Limited agreed to acquire Kelonia Therapeutics, Inc. from Horizons Ventures, Venrock, and Alta Partners for an upfront payment of USD 3.25 billion and will receive additional payment of 3.75 billion upon achieving milestones.


The firm offers a lentiviral vector gene delivery platform to carry genetic payload solely to the appropriate tissue for treating a broad range of diseases such as tumors, cancers, and others.

The acquisition enables Eli Lilly to add an in vivo CAR-T gene delivery platform that engineers cancer-fighting cells directly in patients, reducing reliance on complex lab-based CAR-T manufacturing and expanding its oncology pipeline, including treatments for multiple myeloma.

## Funding rounds

- Series A, Apr 14, 2022, $50M — Alta Partners, Venrock, Horizons Ventures
- Seed, Jun 30, 2020 — Venrock

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Seed, Series A
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A
- Horizons Ventures — Series A